Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OIG Cardiac Implant Review Finds $1.5bn In Medicare Payments For Failed, Recalled Devices

Executive Summary

Medicare was billed $1.5bn, and beneficiaries paid $140 million in copayments, for procedures associated with replacing seven models of defective or failed cardiac implants, according to preliminary results from an ongoing review by the US Department of Health and Human Services’ Office of Inspector General. The "early alert" from OIG’s investigation blamed a lack of device identifiers on claims forms for masking device performance data.

You may also be interested in...

Lack Of Device Identifiers On Recalled Cardiac Devices Cost Medicare $1.5Bn, OIG Says

Medicare lost $1.5bn in claims over a 10-year period to cover procedures to fix or replace seven faulty cardiac devices due to the lack of product-specific information on its claims form for malfunctioning defibrillators and pacemakers, says the US HHS Office of Inspector General. Recalls of Medtronic, Boston Scientific and Abbott/St. Jude Medical cardiac rhythm management devices are likely behind most of the cost.

Recalled Device Costs, Test Payments Focus In OIG Work Plan

The Health & Human Services’ watchdog branch plans to look at a spike in recall costs; Medicare’s progress in implementing lab-test payment reforms; and an ongoing review of FDA’s work on device cybersecurity issues.

Medicare Agency Comes On Board With Adding UDIs To Claims Forms

The acting head of the Center for Medicare and Medicaid Services has signaled his agency's plan to support the effort to get UDIs incorporated as a standard element of insurance claims by signing a letter jointly with the FDA commissioner. Previously, CMS had worried about the move due to the significant system upgrades that hospitals and payers will need to make to support UDIs in claims.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts